Compare WGRX & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGRX | ERNA |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.8M |
| IPO Year | N/A | 2021 |
| Metric | WGRX | ERNA |
|---|---|---|
| Price | $3.01 | $5.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.4K | ★ 30.2K |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.13 |
| 52 Week High | $4.49 | $15.88 |
| Indicator | WGRX | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 42.30 |
| Support Level | $2.81 | $5.16 |
| Resistance Level | $3.40 | $7.94 |
| Average True Range (ATR) | 0.27 | 0.74 |
| MACD | -0.11 | -0.07 |
| Stochastic Oscillator | 29.41 | 26.59 |
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.